Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

December 21, 2021
Open Access

HEXA-018, a Novel Inducer of Autophagy, Rescues TDP-43 Toxicity in Neuronal Cells.

Frontiers in Pharmacology
Shinrye LeeHyung-Jun Kim
December 10, 2021
Open Access

PrP C as a Transducer of Physiological and Pathological Signals.

Frontiers in Molecular Neuroscience
Jessica D PanesCarola Muñoz-Montesino
November 28, 2021

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases.

Claudia RiccardiMariarosa Anna Beatrice Melone
November 15, 2021
Open Access

SC75741, A Novel c-Abl Inhibitor, Promotes the Clearance of TDP25 Aggregates via ATG5-Dependent Autophagy Pathway.

Frontiers in Pharmacology
Dongheng ZhouHongguang Xia
November 3, 2021
Open Access

Natural compounds in the regulation of proteostatic pathways: An invincible artillery against stress, ageing, and diseases.

Acta Pharmaceutica Sinica. B
Arun Upadhyay
October 30, 2021

Disclosing tau tangles using PET imaging: a pharmacological review of the radiotracers available in 2021.

Acta neurologica Belgica
Éléonore Van WambekeBernard Hanseeuw
September 27, 2021

A single copy transgenic mutant FUS strain reproduces age-dependent ALS phenotypes in C. elegans.

MicroPublication. Biology
Audrey LabarreJ Alex Parker
September 16, 2021
Open Access

Lysine-selective molecular tweezers are cell penetrant and concentrate in lysosomes.

Communications Biology
Zizheng LiGal Bitan
September 15, 2021

AAA+ ATPase p97/VCP mutants and inhibitor binding disrupt inter-domain coupling and subsequent allosteric activation.

The Journal of Biological Chemistry
Brian CaffreySriram Subramaniam
August 23, 2021

Decoding expectation and surprise in dementia: the paradigm of music.

Brain Communications
Elia BenhamouJason D Warren
August 16, 2021

The microglial lysosomal system in Alzheimer's disease: Guardian against proteinopathy.

Ageing Research Reviews
Zoë P Van AckerWim Annaert
August 14, 2021

Strategies in the design and development of (TAR) DNA-binding protein 43 (TDP-43) binding ligands.

European Journal of Medicinal Chemistry
Praveen P N RaoFrederic Calon
August 13, 2021
Open Access

Inflammation drives synucleinopathy propagation

Tae-Kyung KimSeung-Jae Lee
August 2, 2021

Neuroimaging Biomarkers of New-Onset Psychiatric Disorders Following Traumatic Brain Injury.

Biological Psychiatry
Andrew R Mayer, Davin K Quinn
July 23, 2021
Open Access

CRISPR/Cas9-engineered Drosophila knock-in models to study VCP diseases.

Disease Models & Mechanisms
Jordan M WallAlyssa E Johnson

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved